bullish
Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level
529 Views09 Dec 2019 17:08
Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Venus Medtech (启明医疗) & Peijia Medical (沛嘉医疗) Placement - Take Your Pick21 Jan 2021
- Venus Medtech (启明医疗) Placement - Already Has Ample Cash but Doesn't Hurt to Have More for R&D02 Sep 2020
- Venus Medtech Lock-Up Expiry: Could Face Selling Pressure11 Jun 2020
- Venus Medtech (启明医疗) IPO: Valuation Still OK at the High End26 Nov 2019
- Venus Medtech (启明医疗) Pre-IPO: Thoughts on Valuation11 Nov 2019
x